JNJ-26990990

JNJ-26990990
Clinical data
Other names	N-((Benzo[b]thien-3-yl)methyl)sulfamide
Identifiers
	IUPAC name 3-[(Sulfamoylamino)methyl]-1-benzothiophene;
CAS Number	877316-38-6 ;
PubChem CID	11687376;
ChemSpider	9862103 ;
UNII	QFG58Y96EP;
ChEBI	CHEBI:580267 ;
ChEMBL	ChEMBL466517 ;
CompTox Dashboard (EPA)	DTXSID20470625 ;
Chemical and physical data
Formula	C9H10N2O2S2
Molar mass	242.31 g·mol−1
	(what is this?) (verify)

JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation follow-up to the marketed drug topiramate.^[1]^[2] It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition.^[1] It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.^[3]

JNJ-26990990 entered phase II clinical trials in October 2007.^[4]

Metabolites and radioactive isotope-labeled derivatives of JNJ-26990990 have also been prepared to support its development.^[5]

References

^ ^a ^b Parker MH, Smith-Swintosky VL, McComsey DF, Huang Y, Brenneman D, Klein B, et al. (December 2009). "Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies". Journal of Medicinal Chemistry. 52 (23): 7528–7536. doi:10.1021/jm801432r. PMID 19388676.
^ WO patent 2006023861, Parker MH, Reitz AB, Maryanoff BE, "Preparation of benzo-fused heteroaryl sulfamide derivatives for the treatment of epilepsy and related disorders", issued 2006-03-02, assigned to Janssen Pharmaceutica
^ "JNJ 26990990 Johnson & Johnson developing anticonvulsant Johnson & Johnson preclinical data". R & D Focus Drug News. September 22, 2008. Archived from the original on October 12, 2012.
^ Fischer J, Ganellin CR (2010). "Chapter 2. Standalone Drugs". Analogue-Based Drug Discovery II. doi:10.1002/9783527630035.ch2.
^ Lin R, Weaner LE, Hoerr DC, Salter R, Gong Y (January 2013). "Expeditious syntheses of stable and radioactive isotope-labeled anticonvulsant agent, JNJ-26990990, and its metabolites". Journal of Labelled Compounds & Radiopharmaceuticals. 56 (1): 22–26. doi:10.1002/jlcr.3013. PMID 24285137.